United States - English - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 40 mg - paroxetine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets, usp in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology —clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets, usp in hospitalized depressed patients have not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 40 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

United States - English - NLM (National Library of Medicine)

proficient rx lp - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - major depressive disorder paroxetine tablets, usp is indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets, usp in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology–clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets, usp in hospitalized depressed patients have not been adequ

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets, usp in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology —clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets, usp in hospitalized depressed patients have not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

padagis us llc - paroxetine mesylate (unii: m711n184je) (paroxetine - unii:41vrh5220h) - paroxetine 7.5 mg - paroxetine capsules are indicated for the treatment of moderate to severe vasomotor symptoms (vms) associated with menopause. limitation of use: paroxetine capsules are not indicated for the treatment of any psychiatric condition. paroxetine capsules contain a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. the safety and efficacy of this lower dose of paroxetine in paroxetine capsules have not been established for any psychiatric condition. patients who require paroxetine for treatment of a psychiatric condition should discontinue paroxetine capsules and initiate a paroxetine-containing medication that is indicated for such use. concomitant use of an maoi with paroxetine capsules or within 14 days of stopping treatment with paroxetine capsules is contraindicated because of an increased risk of serotonin syndrome. the use of paroxetine capsules within 14 days o

United States - English - NLM (National Library of Medicine)

solco healthcare llc - paroxetine mesylate (unii: m711n184je) (paroxetine - unii:41vrh5220h) - paroxetine 7.5 mg - paroxetine capsules are indicated for the treatment of moderate to severe vasomotor symptoms (vms) associated with menopause. limitation of use : paroxetine capsules are not indicated for the treatment of any psychiatric condition. paroxetine capsules contain a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. the safety and efficacy of this lower dose of paroxetine in paroxetine capsules have not been established for any psychiatric condition. patients who require paroxetine for treatment of a psychiatric condition should discontinue paroxetine capsules and initiate a paroxetine-containing medication that is indicated for such use. concomitant use of an maoi with paroxetine capsules or within 14 days of stopping treatment with paroxetine capsules is contraindicated because of an increased risk of serotonin syndrome. the use of paroxetine capsules within 14 days

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; magnesium stearate; copovidone; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; sodium starch glycollate; purified talc - paroxetine gh is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; titanium dioxide; sodium starch glycollate; colloidal anhydrous silica; hypromellose; copovidone; purified talc - paroxetine sandoz is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine is indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. clinical pharmacology: clinical trials the effects of paroxetine in hospitalized depressed patients have not been adequately studied. the efficacy of